Lipocine Inc.

Canaccord Genuity acts as joint bookrunner for US$30.2 million follow-on offering of common stock by Lipocine Inc.

Canaccord Genuity is pleased to announce that on April 29, 2015, it completed a follow-on offering of common stock for Lipocine Inc. (NASDAQ: LPCN).  The company issued a total of 4,650,000 shares of common stock at a price of $6.50 per share. In addition, Lipocine has granted the underwriters a 30-day option to purchase up to an additional 697,500 shares of common stock at the initial public offering price. Canaccord Genuity acted as joint bookrunner for the offering. Lipocine intends to use the net proceeds from this offering for general corporate purposes, which may include additions to working capital and capital expenditures.

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's lead product candidate, LPCN 1021, demonstrated positive top-line efficacy results in Phase 3 testing and is targeted for testosterone replacement therapy, or TRT. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate (HPC) product indicated for the prevention of recurrent preterm birth, is currently in Phase 1 testing.